{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:05:05Z","timestamp":1790280305502,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lungcan.2026.109588","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:59:33Z","timestamp":1789178373000},"page":"109588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term safety of first-line osimertinib plus platinum\u2013pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2"],"prefix":"10.1016","author":[{"given":"David","family":"Planchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.-H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Valdiviezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Leiva","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bivas","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po Hao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virote","family":"Sriuranpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Koubkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Dix J.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Escriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tho Vinh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeni","family":"Ner\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Donachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Khullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azura","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Albayaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Khoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lungcan.2026.109588_b0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109588_b0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.23.02744","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109588_b0015","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"E.G.C.E.a. clinicalguidelines@esmo.org, Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109588_b0020","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1200\/JCO-25-02822","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, 2026.3.0","volume":"44","author":"Puri","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109588_b0025","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109588_b0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","volume":"394","author":"Janne","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109588_b0035","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109588_b0040","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109588_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100271","article-title":"Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced\/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study","volume":"6","author":"Planchard","year":"2021","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109588_b0050","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1200\/JCO-24-02785","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living Guideline, version 2024.3","volume":"43","author":"Owen","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109588_b0055","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s11912-025-01723-w","article-title":"Who truly benefits from first-line intensification in EGFR-mutant NSCLC?","volume":"27","author":"Maffezzoli","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.lungcan.2026.109588_b0060","unstructured":"U.S. Food and Drug Administration. PARAPLATIN\u00ae (carboplatin) Injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2010. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020452s005lbl.pdf. Accessed 28 May 2026."},{"key":"10.1016\/j.lungcan.2026.109588_b0065","unstructured":"U.S. Food and Drug Administration. CISPLATIN for injection, prescribing information. Silver Spring, MD: FDA; 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/018057s092lbl.pdf. Accessed 28 May 2026."},{"key":"10.1016\/j.lungcan.2026.109588_b0070","unstructured":"U.S. Food and Drug Administration. Pemetrexed for injection, prescribing information. Silver Spring, MD: FDA; 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214657s006lbl.pdf. Accessed 28 May 2026."},{"key":"10.1016\/j.lungcan.2026.109588_b0075","series-title":"TAGRISSO (osimertinib) tablets, for oral use: prescribing information","author":"U.S. Food and Drug Administration","year":"2024"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109588_b0080","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109588_b0085","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cllc.2014.06.007","volume":"15","author":"Pujol","year":"2014","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109588_b0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109588_b0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/03007995.2018.1439462","volume":"34","author":"Middleton","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109588_b0100","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/JTO.0b013e318267cf84","article-title":"Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"7","author":"Gridelli","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109588_b0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol.."},{"key":"10.1016\/j.lungcan.2026.109588_b0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"de Rouw","year":"2020","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109588_b0115","first-page":"2144","article-title":"Patient-reported outcomes in FLAURA2: osimertinib with or without chemotherapy in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer","volume":"32","author":"Gray","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109588_b0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109588_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037229","article-title":"Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:57:00Z","timestamp":1790279820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"alternative-id":["S0169500226006495"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109588","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety of first-line osimertinib plus platinum\u2013pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109588"}}